Senti Biosciences is trading 5.31% lower at $0.18, with no confirmed catalyst for the October 26 move. - No fresh company-specific announcement explaining the move surfaced; merger and reverse-split approvals had been reported earlier. - The latest filings listed on its investor-relations page were dated October 23 or earlier. Broader indices were modestly higher, so available evidence does not point to a broad-market decline as the cause.